References
1. Ebrahimi F., Christ-Crain M. Metabolic syndrome and hypogonadism-two peas in a pod. Swiss Med Wkly. 2016; 146: w142837.
2. Rastrelli G., Filippi S., Sforza A., et al. Metabolic syndrome in male hypogonadism. Front Horm Res. 2018; 49: 131–55.
3. Mulligan T., Frick M.F., Zuraw Q.C., et al. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract. 2006; 60 (7): 762–9.
4. Khripun I.A., Vorob’ev S.V. Hypogonadism as type 2 diabetes mellitus comorbidity. FOCUS Focus Endokrinlolgiya [Focus Endocrinology]. 2020; 1 (1): 16–20. DOI: https://doi.org/10.47407/ef2020.1.1.0002 (in Russian)
5. Herrero A., Marcos M., Galindo P., et al. Clinical and biochemical correlates of male hypogonadism in type 2 diabetes. Andrology. 2018; 6 (1): 58–63.
6. Raza M.T., Sharif S., Khan Z.A., et al. Frequency of hypogonadism in type 2 diabetes mellitus patients with and without coronary artery disease. Cureus. 2019; 11 (12): e6500.
7. Zhang J., Li X, Cai Z., et al. Association between testosterone with type 2 diabetes in adult males, a meta-analysis and trial sequential analysis. Aging Male. 2020; 23 (5): 607–18.
8. Yao Q.M., Wang B., An X.F., et al. Testosterone level and risk of type 2 diabetes in men: a systematic review and meta-analysis. Endocr Connect. 2018; 7 (1): 220–31.
9. Blaya R., Thomaz L.D., Guilhermano F., et al. Total testosterone levels are correlated to metabolic syndrome components. Aging Male. 2016; 9 (2): 85–9.
10. Cunningham G.R. Testosterone and metabolic syndrome. Asian J Androl. 2015; 17 (2): 192–6.
11. Khripun I.A., Vorob’ev S.V., Morgunov M.N., Kogan M.I. Endothelial function in men with type 2 diabetes without clinical signs of cardiovascular disease. Sakharniy diabet [Diabetes Mellitus]. 2016; 19 (5): 383–387. DOI: https://doi.org/10.14341/dm8017 (in Russian)
12. Ametov A.S. Diabetes mellitus type 2. Problems and solutions. 3rd ed., revised and additional. Moscow: GEOTAR-Media, 2015; (1): 352 p. (in Russian)
13. Khripun I.A., Vorob’ev S.V., Puzyreva V.P., et al. Dysfunction of endothelium, as a result of androgen deficiency in men with type 2 diabetes. Sovremennye problemy nauki i obrazovaniya [Modern Problems of Science and Education]. 2015; (6): 220. (in Russian)
14. Dedov I.I., Shestakova M.V., Mayorov A. Yu., et al. Algorithms for specialized medical care for patients with diabetes mellitus. Sakharniy diabet [Diabetes Mellitus]. 2017; 20 (1S): 1–121. (in Russian)
15. Mel’nichenko G.A., Shestakova M.V., Rozhivanov R.V. The prevalence of hypogonadism in men with diabetes mellitus (DM) type 2 in clinical practice. Sakharniy diabet [Diabetes Mellitus]. 2019; 22 (2): 127–30. DOI: https://doi.org/10.14341/DM9944 (in Russian)
16. Chernova M.O., Esaulenko D.I., Rozhivanova E.R., Rozhivanov R.V., Mel’nichenko G.A., Shestakova M.V., et al. Clinical and epidemiological characteristics of male hypogonadism in type 2 diabetes in Russia: combined analysis of study data for the period 2005-2022. Sakharniy diabet [Diabetes Mellitus]. 2023; 26 (1): 4–12. DOI: https://doi.org/10.14341/DM12978 (in Russian)